Ensysce Biosciences, Inc. (ENSC)
0.4811
+0.01
(+1.71%)
USD |
NASDAQ |
Sep 09, 11:40
Ensysce Biosciences Max Drawdown (5Y) : 100.00% for Aug. 31, 2026
Max Drawdown (5Y) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| August 31, 2026 | 100.00% |
| July 31, 2026 | 100.00% |
| June 30, 2026 | 100.00% |
| May 31, 2026 | 100.00% |
| April 30, 2026 | 100.00% |
| March 31, 2026 | 100.00% |
| February 28, 2026 | 100.00% |
| January 31, 2026 | 100.00% |
| December 31, 2025 | 100.00% |
| November 30, 2025 | 100.00% |
| October 31, 2025 | 100.00% |
| September 30, 2025 | 100.00% |
| August 31, 2025 | 100.00% |
| July 31, 2025 | 100.00% |
| June 30, 2025 | 100.00% |
| May 31, 2025 | 100.00% |
| April 30, 2025 | 100.00% |
| March 31, 2025 | 100.00% |
| February 28, 2025 | 100.00% |
| January 31, 2025 | 100.00% |
| December 31, 2024 | 100.00% |
| November 30, 2024 | 100.00% |
| October 31, 2024 | 100.00% |
| September 30, 2024 | 100.00% |
| August 31, 2024 | 99.99% |
| Date | Value |
|---|---|
| July 31, 2024 | 99.99% |
| June 30, 2024 | 99.99% |
| May 31, 2024 | 99.99% |
| April 30, 2024 | 99.99% |
| March 31, 2024 | 99.99% |
| February 29, 2024 | 99.99% |
| January 31, 2024 | 99.99% |
| December 31, 2023 | 99.99% |
| November 30, 2023 | 99.99% |
| October 31, 2023 | 99.98% |
| September 30, 2023 | 99.98% |
| August 31, 2023 | 99.97% |
| July 31, 2023 | 99.97% |
| June 30, 2023 | 99.97% |
| May 31, 2023 | 99.96% |
| April 30, 2023 | 99.94% |
| March 31, 2023 | 99.92% |
| February 28, 2023 | 99.90% |
| January 31, 2023 | 99.87% |
| December 31, 2022 | 99.87% |
| November 30, 2022 | 99.60% |
| October 31, 2022 | 99.33% |
| September 30, 2022 | 99.10% |
| August 31, 2022 | 98.32% |
| July 31, 2022 | 98.25% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 88.96% |
| Oncolytics Biotech, Inc. | 92.83% |
| Sangamo Therapeutics, Inc. | 99.68% |
| Sarepta Therapeutics, Inc. | 93.33% |
| Anixa Biosciences, Inc. | 70.17% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -99.76 |
| Beta (5Y) | 0.9762 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 153.7% |
| Historical Sharpe Ratio (5Y) | -0.5916 |
| Historical Sortino (5Y) | -1.573 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 54.32% |